One Week Sustained In Vivo Therapeutic Release and Safety of Novel Extended‐Wear Silicone Hydrogel Contact Lenses
Source abstract
Abstract
Abstract Since the seminal work of Wichterle in 1965 describing the first soft contact lenses and their potential for ocular drug delivery, the field has yet to realize his vision. Maintaining all lens commercial properties combined with a mechanism for controlled drug release of therapeutically relevant concentrations for duration of wear is a major challenge. Here, successful in vivo week‐long sustained release of a small molecular weight therapeutic in rabbits from extended‐wear silicone hydrogel contact lenses meeting all commercial specifications by utilizing a novel macromolecular memory strategy is reported for the first time. Lens‐treated eyes show a continuous, therapeutically relevant bromfenac tear concentration of 256.4 ± 23.1 µg mL−1 for 8 days. Bromday (bromfenac ophthalmic solution, 0.09%, Bausch+Lomb) topical drops exhibit a quick peak concentration of 269.3 ± 85.7 µg mL−1 and 100 min duration. Bioavailability (AUC0‐8days) and mean residence time of lenses are 26 and 155 times higher than drops, respectively. Lenses are safe, well tolerated, and no corneal histological differences are observed. This work highlights the enormous potential of drug releasing lenses as a platform strategy, and offers a new dropless clinical strategy for post‐cataract, uveitis, post‐LASIK, and corneal abrasion treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
OcuMedic, Inc. 107 Gilbreth Parkway Mullica Hill NJ 08062 USA
Biomimetic & Biohybrid Materials Biomedical Devices and Drug Delivery Laboratories Department of Biomedical Engineering Rowan University Glassboro NJ 08028 USA
School of Osteopathic Medicine Rowan University Stratford NJ 08084 USA
Veterinary Ophthalmology Services Nashville TN 37204 USA
Department of Chemical Engineering Rowan University Glassboro NJ 08028 USA
References (48)
Show source-provided references
1. 2019
2. 10.1016/S2214-109X(20)30488-510.1016/S2214-109X(20)30488-5 ↗
3. B.Morgan R.Lee A.ReinLLS Health CDMO 2019.
4. 10.5497/wjp.v2.i2.4710.5497/wjp.v2.i2.47 ↗
5. 10.1016/j.survophthal.2003.12.00910.1016/j.survophthal.2003.12.009 ↗
6. 10.1016/0002-9394(79)90145-410.1016/0002-9394(79)90145-4 ↗
7. 10.1007/s13346-016-0339-210.1007/s13346-016-0339-2 ↗
8. 10.1016/j.addr.2006.07.02710.1016/j.addr.2006.07.027 ↗
9. 10.1046/j.1440-1681.2000.03288.x10.1046/j.1440-1681.2000.03288.x ↗
10. 10.1208/s12248-010-9183-310.1208/s12248-010-9183-3 ↗
11. 10.1038/clpt.2008.29710.1038/clpt.2008.297 ↗
12. 10.4172/2155-9570.100057210.4172/2155-9570.1000572 ↗
13. 10.1016/j.biomaterials.2009.08.02510.1016/j.biomaterials.2009.08.025 ↗
14. 10.1167/iovs.13-1174710.1167/iovs.13-11747 ↗
15. 10.1073/pnas.181488911610.1073/pnas.1814889116 ↗
16. 10.1002/smll.20130343310.1002/smll.201303433 ↗
17. 10.1016/j.biomaterials.2017.02.01610.1016/j.biomaterials.2017.02.016 ↗
18. 10.1038/185117a010.1038/185117a0 ↗
19. O.Wichterle D.Lím U.S. Patent US3220960 1965.
20. 10.1016/j.jddst.2021.10241310.1016/j.jddst.2021.102413 ↗
21. 10.1016/0002-9394(73)91015-510.1016/0002-9394(73)91015-5 ↗
22. 10.1136/bjo.58.7.67410.1136/bjo.58.7.674 ↗
23. 10.1016/0002-9394(72)90062-110.1016/0002-9394(72)90062-1 ↗
24. 10.1016/j.ijpharm.2017.11.05910.1016/j.ijpharm.2017.11.059 ↗
25. 10.1016/j.ijpharm.2017.03.08310.1016/j.ijpharm.2017.03.083 ↗
26. 10.1080/09205063.2014.95801610.1080/09205063.2014.958016 ↗
27. 10.1016/j.ejpb.2017.10.01610.1016/j.ejpb.2017.10.016 ↗
28. 10.3109/10717544.2016.113834210.3109/10717544.2016.1138342 ↗
29. 10.1016/S1773-2247(11)50062-010.1016/S1773-2247(11)50062-0 ↗
30. 10.1016/j.jconrel.2011.09.08710.1016/j.jconrel.2011.09.087 ↗
31. 10.1016/j.biomaterials.2011.04.04410.1016/j.biomaterials.2011.04.044 ↗
32. 10.1016/j.ejpb.2012.01.01510.1016/j.ejpb.2012.01.015 ↗
33. 10.1007/s11095-008-9818-610.1007/s11095-008-9818-6 ↗
34. 10.1016/j.ejpb.2008.01.03610.1016/j.ejpb.2008.01.036 ↗
35. 10.1097/OPX.000000000000084910.1097/OPX.0000000000000849 ↗
36. 10.1002/app.3956810.1002/app.39568 ↗
37. 10.1002/macp.20130038610.1002/macp.201300386 ↗
38. 10.1097/ICL.0b013e318275452b10.1097/ICL.0b013e318275452b ↗
39. 10.1016/S1542-0124(12)70262-810.1016/S1542-0124(12)70262-8 ↗
40. 10.1111/j.1475-1313.2005.00342.x10.1111/j.1475-1313.2005.00342.x ↗
41. Lampa M. · Contact Lens Spectrum · 2017 · 32 · 30
42. U.S. FDA PMA P010019 S003 2004.
43. Whittaker A. L. · J. Am. Assoc. Lab. Anim. Sci. · 2015 · 54 · 783
44. 10.1097/ICO.0b013e3181c2964c10.1097/ICO.0b013e3181c2964c ↗
45. 10.1002/jps.260062071210.1002/jps.2600620712 ↗
46. Mishima S. · Invest. Ophthalmol. Visual Sci. · 1966 · 5 · 264
47. 10.1097/ICL.0b013e31815788d710.1097/ICL.0b013e31815788d7 ↗
48. 10.1111/j.1444-0938.2012.00801.x10.1111/j.1444-0938.2012.00801.x ↗